Repare Historical Income Statement

RPTX Stock

USD 3.28 0.04 1.20%

Historical analysis of Repare Therapeutics income statement accounts such as Selling General Administrative of 18.4 M, Total Revenue of 30 M, Other Operating Expenses of 84.1 M or Research Development of 140.3 M can show how well Repare Therapeutics performed in making a profits. Evaluating Repare Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Repare Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Repare Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Repare Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repare Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.

About Repare Income Statement Analysis

Repare Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Repare Therapeutics shareholders. The income statement also shows Repare investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Repare Therapeutics Income Statement Chart

At this time, Repare Therapeutics' Interest Income is fairly stable compared to the past year. Interest Expense is likely to rise to about 9.9 M in 2024, whereas Tax Provision is likely to drop slightly above 2.8 M in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Repare Therapeutics. It is also known as Repare Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Repare Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Repare Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repare Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.At this time, Repare Therapeutics' Interest Income is fairly stable compared to the past year. Interest Expense is likely to rise to about 9.9 M in 2024, whereas Tax Provision is likely to drop slightly above 2.8 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.5M	2.0M	1.9M	1.2M
Total Operating Expenses	116.3M	151.6M	167.4M	84.1M

Reconciled Depreciation Total Operating Expenses

Repare Therapeutics income statement Correlations

	Interest Income	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Net Interest Income	Non Operating Income Net Other	Selling And Marketing Expenses
Interest Income		0.38	0.61	0.64	-0.66	-0.6	-0.65	0.8	-0.66	0.64	0.59	-0.6	0.97	-0.58	-0.44	-0.47	0.96	0.99	0.73	-0.91
Depreciation And Amortization	0.38		0.92	0.89	-0.63	-0.69	-0.64	0.83	-0.62	0.9	0.91	-0.61	0.56	-0.7	0.25	0.33	0.3	0.47	0.86	-0.26
Selling General Administrative	0.61	0.92		1.0	-0.78	-0.81	-0.78	0.93	-0.77	1.0	0.99	-0.75	0.76	-0.81	0.0	0.06	0.56	0.69	0.92	-0.43
Other Operating Expenses	0.64	0.89	1.0		-0.77	-0.8	-0.78	0.93	-0.76	1.0	0.99	-0.74	0.78	-0.8	-0.02	0.04	0.58	0.71	0.93	-0.45
Operating Income	-0.66	-0.63	-0.78	-0.77		0.99	1.0	-0.85	1.0	-0.77	-0.76	1.0	-0.77	0.99	0.58	0.51	-0.77	-0.73	-0.82	0.71
Net Income From Continuing Ops	-0.6	-0.69	-0.81	-0.8	0.99		0.99	-0.85	0.99	-0.8	-0.8	0.99	-0.73	1.0	0.5	0.42	-0.7	-0.67	-0.84	0.64
Ebit	-0.65	-0.64	-0.78	-0.78	1.0	0.99		-0.85	1.0	-0.78	-0.77	1.0	-0.77	0.99	0.57	0.49	-0.76	-0.72	-0.82	0.7
Research Development	0.8	0.83	0.93	0.93	-0.85	-0.85	-0.85		-0.84	0.93	0.93	-0.81	0.91	-0.85	-0.18	-0.14	0.77	0.87	0.97	-0.72
Ebitda	-0.66	-0.62	-0.77	-0.76	1.0	0.99	1.0	-0.84		-0.76	-0.76	1.0	-0.76	0.99	0.59	0.52	-0.77	-0.72	-0.81	0.71
Total Operating Expenses	0.64	0.9	1.0	1.0	-0.77	-0.8	-0.78	0.93	-0.76		0.99	-0.74	0.78	-0.8	-0.02	0.04	0.58	0.71	0.93	-0.45
Reconciled Depreciation	0.59	0.91	0.99	0.99	-0.76	-0.8	-0.77	0.93	-0.76	0.99		-0.73	0.76	-0.8	0.03	0.08	0.54	0.68	0.91	-0.43
Income Before Tax	-0.6	-0.61	-0.75	-0.74	1.0	0.99	1.0	-0.81	1.0	-0.74	-0.73		-0.71	0.99	0.59	0.51	-0.72	-0.67	-0.79	0.66
Total Other Income Expense Net	0.97	0.56	0.76	0.78	-0.77	-0.73	-0.77	0.91	-0.76	0.78	0.76	-0.71		-0.71	-0.38	-0.38	0.94	0.99	0.83	-0.89
Net Income	-0.58	-0.7	-0.81	-0.8	0.99	1.0	0.99	-0.85	0.99	-0.8	-0.8	0.99	-0.71		0.49	0.4	-0.68	-0.66	-0.83	0.63
Income Tax Expense	-0.44	0.25	0.0	-0.02	0.58	0.5	0.57	-0.18	0.59	-0.02	0.03	0.59	-0.38	0.49		0.99	-0.66	-0.43	-0.12	0.63
Gross Profit	-0.47	0.33	0.06	0.04	0.51	0.42	0.49	-0.14	0.52	0.04	0.08	0.51	-0.38	0.4	0.99		-0.67	-0.44	-0.06	0.64
Cost Of Revenue	0.96	0.3	0.56	0.58	-0.77	-0.7	-0.76	0.77	-0.77	0.58	0.54	-0.72	0.94	-0.68	-0.66	-0.67		0.96	0.68	-0.95
Net Interest Income	0.99	0.47	0.69	0.71	-0.73	-0.67	-0.72	0.87	-0.72	0.71	0.68	-0.67	0.99	-0.66	-0.43	-0.44	0.96		0.78	-0.91
Non Operating Income Net Other	0.73	0.86	0.92	0.93	-0.82	-0.84	-0.82	0.97	-0.81	0.93	0.91	-0.79	0.83	-0.83	-0.12	-0.06	0.68	0.78		-0.62
Selling And Marketing Expenses	-0.91	-0.26	-0.43	-0.45	0.71	0.64	0.7	-0.72	0.71	-0.45	-0.43	0.66	-0.89	0.63	0.63	0.64	-0.95	-0.91	-0.62

Click cells to compare fundamentals

Repare Therapeutics Account Relationship Matchups

Repare Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Tax Provision	195K	(1.3M)	(1.7M)	15.1M	5.5M	2.8M
Interest Income	712K	240K	259K	5.6M	13.2M	13.8M
Depreciation And Amortization	(107K)	1.8M	3.3M	4.2M	2.0M	1.8M
Interest Expense	68K	207K	1.4M	8.2M	9.4M	9.9M
Selling General Administrative	5.4M	14.3M	26.2M	32.6M	33.8M	18.4M
Other Operating Expenses	26.4M	54.4M	116.3M	151.6M	167.6M	84.1M
Operating Income	(26.4M)	(54.3M)	(108.7M)	(19.8M)	(116.2M)	(110.4M)
Net Income From Continuing Ops	(27.2M)	(53.4M)	(106.9M)	(29.0M)	(97.4M)	(92.6M)
Ebit	(26.4M)	(55.2M)	(110.5M)	(22.0M)	(116.2M)	(110.4M)
Research Development	21.0M	40.1M	90.0M	119.1M	133.6M	140.3M
Ebitda	(26.5M)	(53.4M)	(107.2M)	(17.8M)	(114.3M)	(108.6M)
Total Operating Expenses	26.4M	54.4M	116.3M	151.6M	167.4M	84.1M
Reconciled Depreciation	605K	897K	1.5M	2.0M	1.9M	1.2M
Income Before Tax	(27.0M)	(54.7M)	(108.6M)	(13.9M)	(103.2M)	(98.0M)
Total Other Income Expense Net	(644K)	(440K)	74K	5.9M	13.0M	13.7M
Net Income Applicable To Common Shares	(27.2M)	(53.4M)	(106.9M)	(29.0M)	(26.1M)	(27.4M)
Net Income	(27.2M)	(53.4M)	(106.9M)	(29.0M)	(93.8M)	(89.1M)
Income Tax Expense	195K	(1.3M)	(1.7M)	15.1M	(9.4M)	(8.9M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Repare Historical Income Statement

About Repare Income Statement Analysis

Repare Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Repare Therapeutics income statement Correlations

Repare Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Repare Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Repare Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income

Selling And Marketing Expenses	- 0.95	Cost Of Revenue
Selling And Marketing Expenses	- 0.91	Net Interest Income
Selling And Marketing Expenses	- 0.91	Interest Income
Selling And Marketing Expenses	- 0.89	Total Other Income Expense Net
Net Income	- 0.85	Research Development
Research Development	- 0.85	Ebit